Kepos Capital’s NovoCure NVCR Stock Holding History

Kepos Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,127	Closed	-$264K	–	267
2019 Q4	$264K	Hold	3,127	–	–	0.02%	290
2019 Q3	$234K	Buy	+3,127	New	+$250K	0.02%	264

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Kepos Capital's NVCR Position: Q1 2020 in Review

Kepos Capital sold out of NovoCure (NVCR) in Q1 2020, closing a stake of 3,127 shares — an estimated $264K sold.

Kepos Capital first reported a position in NVCR in Q3 2019 and held it in 2 quarters. The position peaked at $264K in Q4 2019. 271 funds tracked by Wall St. Rank hold NVCR as of Q1 2020.

Kepos Capital reported no remaining NovoCure position as of Q1 2020 after selling out during the quarter.
Kepos Capital sold 3,127 NovoCure shares in Q1 2020, an estimated $264K.
Kepos Capital first reported a position in NovoCure in Q3 2019 and held it in 2 quarters.
Kepos Capital's NovoCure position peaked at $264K in Q4 2019.
271 funds tracked by Wall St. Rank held NovoCure as of Q1 2020.

Based on Kepos Capital's 13F filing for Q1 2020, filed 12 May 2020.